ESPR Stock Recent News

Esperion Therapeutics (ESPR) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to loss of $0.76 per share a year ago.

Esperion Therapeutics (ESPR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ANN ARBOR, Mich., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report fourth quarter and full year 2023 financial results before the market opens on Tuesday, February 27, 2024.

Esperion Therapeutics' stock gapped down after news of a stock offering but fortunately never reached the $1.50 offering price. The presentation at the JP Morgan Healthcare Conference provided little new information and failed to boost the stock. The Q&A session provided some insights, including information about utilization management headwinds and the company's digital consumer campaign.

Esperion Therapeutics (NASDAQ: ESPR ) stock is falling on Friday after the pharmaceutical company announced details for a public offering of its shares. This public offering has Esperion Therapeutics selling 56.7 million shares of ESPR stock for $1.50 each.

Esperion Therapeutics has a potential blockbuster drug that is gaining traction among the medical community. The company's main drugs, NEXLIZET and NEXLETOL, have been approved by the FDA and offer alternatives to statins for lowering LDL cholesterol. Recent developments, including an expanded labeling and influential endorsements from doctors like Peter Attia, suggest potential growth for the company.

Daiichi Sankyo amends its existing collaboration with Esperion (ESPR), including the resolution of a commercial dispute over milestone payments. This amendment is valued at $125 million.

Esperion Therapeutics has reached a deal with Daiichi Sankyo to resolve a commercial dispute with an amendment to their ongoing collaboration.  Daiichi Sankyo Europe GmbH, the company's European arm, agreed to pay Esperion $100 million ahead of an expected Type II(a) variation approval by the European Medicines Agency for a pair of drugs, NILEMDO and NUSTENDI.

Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock?

Esperion Therapeutics reports strong Q3 earnings for bempedoic acid, with revenues of $20.3M and impressive growth in retail Rx and new-to-brand prescriptions. Anticipated label expansion in the US and EU in 2024 could significantly broaden bempedoic acid's market reach, with a potential addressable market of 70 million patients. An ongoing legal dispute with Daiichi presents a potential upside for Esperion, with the possibility of a favorable ruling that could de-risk a $300M milestone payment.